Pooled analysis of three clinical trials confirms rimegepant 75 mg is effective and safe for acute migraine treatment in Black or African American adults, an underrepresented population in migraine research.
Efficacy confirmed in underrepresented groupRimegepant 75 mg effective for acute migraine in Black/African American adults across 3 pooled RCTs
What the researchers found
Rimegepant 75 mg demonstrated efficacy and safety for acute migraine treatment in Black or African American adults, addressing a critical evidence gap from clinical trial underrepresentation.
Why it matters
Black and African American adults have similar migraine rates as White populations but are dramatically underrepresented in clinical trials. This analysis ensures treatment evidence exists for this population.
How the study worked
Post hoc pooled subgroup analysis of three randomized, placebo-controlled clinical trials; rimegepant 75 mg vs placebo.
What this study cannot tell us
Post hoc subgroup analysis has less statistical power than primary analysis; may not capture all within-group diversity; limited to US-based trial participants.
How to read the evidence
Post hoc subgroup analysis of three RCTs — provides important but secondary-level evidence; prospective diverse trials are still needed.
When this study was published
Published in 2026, contributing to the growing focus on health equity in migraine treatment research.
The bigger picture
This analysis is part of a broader push to ensure clinical trial evidence represents the diversity of patients who will use these medications, addressing health equity in migraine care.
Questions still open
- Why are Black and African American adults underrepresented in migraine trials despite similar disease prevalence?
- Are there differences in optimal rimegepant dosing across racial groups?
Common questions
What is rimegepant and how does it treat migraine?
Why is this subgroup analysis important?
Read the original research
Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo-controlled clinical trials.
Headache
Citation
Charleston, Larry; Armand, Cynthia E; Monteith, Teshamae S; O'Brien, Hope L; Abbott, Chandra C; Pixton, Glenn C; Fullerton, Terence. (2026). Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo-controlled clinical trials.. Headache. https://doi.org/10.1111/head.70034